When was Synaptic founded?

Synaptic was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Synaptic located?

Synaptic is headquartered in New York City, United States.

Is Synaptic a funded company?

Synaptic is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Sep 18, 2015.

When was the latest funding round of Synaptic?

Synaptic's latest funding was a $***** Seed round on Sep 18, 2015, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $632M in funding in 2026 to date.

Where does Synaptic rank among its competitors?

Synaptic ranks 58th amongst 84 active competitors, of which 16 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Cavalry Biosciences, which secured $275K in Jan, 2025.

Who are the top competitors of Synaptic?

Synaptic's top competitors include HitGen, Slingshot Bioscience and InterAx Biotech. Among them, Cavalry Biosciences secured the most recent funding round in January, 2025.

Synaptic - 2026 Company Profile, Funding & Competitors

Synaptic is a deadpooled company based in New York City (United States), founded in 2015. It operates as a Developing a novel drug discovery platform. Synaptic has raised $500K in funding. The company has 84 active competitors, including 16 funded and 8 that have exited. Its top competitors include companies like HitGen, Slingshot Bioscience and InterAx Biotech.

Company Details

Beagle Bioscience, an early stage startup, is developing a novel drug discovery platform. The company is founded in 2017 and has not disclosed any details about their technology, disease areas focus as of June 2017.

Website: synaptic.bio
Social
Email ID: *****@synaptic.bio

Key Metrics

Founded Year

2015

Location

New York City, United States

Stage

Deadpooled

Total Funding

$500K in 1 round

Latest Funding Round

Seed, Sep 18, 2015, $*****

Ranked

58^th among 84 active competitors

Similar Companies

HitGen & 86 more

View Synaptic's full profile

Synaptic has raised a total funding of $500K over 1 round.

Here is the list of recent funding rounds of Synaptic:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 18, 2015	3089327	Seed	1211751	3860701	6354398	8606126

Access funding benchmarks and valuations. Sign up today!

View details of Synaptic's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Synaptic include HitGen, Slingshot Bioscience and InterAx Biotech. Here is the list of Top 10 competitors of Synaptic, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HitGen 2012, Lanzhou (China), Public	Developer of DNA encoded libraries for drug discovery	$39.1M	CDH, Shiyu & 2 others	57/100
2nd	Slingshot Bioscience 2012, Berkeley (United States), Series A	Developer of next-generation synthetic cells for diagnostics and therapeutics	$46.4M	Northpond Ventures, Arch Venture Partners ... & 2 others	56/100
3rd	InterAx Biotech 2016, Villigen (Switzerland), Series A	Arrestin-based biosensors and computational methods for GPCR based drug discovery	$3.19M	Verve Ventures, Venture Kick & 5 others	53/100
4th	Sequence Bio 2013, St John s (Canada), Seed	Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases and develop medicines.	$5.47M	Y Combinator, DCVC & 5 others	45/100
5th	Vectus Biosystems 2005, Rosebery (Australia), Public	Develops drug discovery platform	-	-	44/100
6th	StemoniX 2014, San Diego (United States), Acquired	Engineering human brain and nerve models for neurological insights	$33.7M	EvoNexus, Gopher Angels & 19 others	44/100
7th	Aucta Pharmaceuticals 2012, New Brunswick (United States), Seed	Innovating enhanced therapeutics using technology for specialty brand and generic products	-	Shanghai Changjiang Guohong Investment Management, SDIC Venture Capital Management ... & 3 others	42/100
8th	ZoBio 2004, Leiden (Netherlands), Acquired	Provider of fragment-based drug discovery services	-	Europa, Libertatis Ergo Holding	40/100
9th	Signal Pharmaceuticals 1993, San Diego (United States), Acquired	Discoverer of drugs to regulate disease-related genes	$12M	The Vertical Group, Venrock & 10 others	40/100
10th	Cavalry Biosciences 2021, San Francisco (United States), Series A	Developer of therapeutics to treat chronic and rare diseases	-	Venrock, Mission BioCapital & 2 others	40/100
58th	Synaptic 2015, New York City (United States), Deadpooled	Developing a novel drug discovery platform	$500K	-	17/100